CAPECITABINE VIATRIS 500 mg

DRUG2 trials

Sponsors

Fondation Franc.Cancerologie Digestive, Associazione Italiana Per Lo Studio Del Pancreas

Conditions

microsatellite stable (MSS) colorectal cancer with liver-dominant metastasispancreatic ductal adenocarcinoma

Phase 2

A PROSPECTIVE, MULTICENTER, OPEN-LABEL, PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OR SELECTIVE INTERNAL RADIATION THERAPY PLUS XELOX, BEVACIZUMAB AND ATEZOLIZUMAB ( IMMUNE CHECKPOINT INHIBITOR) IN PATIENTS WITH LIVER-DOMINANT METASTATIC COLORECTAL CANCER

Not yet recruitingCTIS2024-517204-11-00

Fondation Franc.Cancerologie Digestivemicrosatellite stable (MSS) colorectal cancer with liver-dominant metastasis

Target: 52Updated: 2024-08-30

Phase 3

A randomized phase III trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma (PDAC)

Not yet recruitingCTIS2024-519031-42-00

Associazione Italiana Per Lo Studio Del Pancreaspancreatic ductal adenocarcinoma

Target: 261Updated: 2024-11-18

Related Papers

Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial.

2025-11-20